- In June 2024, Bio-Rad Laboratories launched new anti-idiotypic and anti-monomethyl auristatin E (MMAE) antibodies to improve the sensitivity and specificity of assays used in therapeutic drug monitoring. These advancements aim to enhance the accuracy of measuring biologic drug levels and assessing patient immune responses
- In October 2023, ProciseDx obtained FDA clearance for its innovative tests designed to monitor levels of biologic drugs, including Humira and Remicade. This approval marks a significant advancement in therapeutic drug monitoring, particularly for chronic conditions such as rheumatoid arthritis and Crohn's disease
- In September 2023, Axithra, a spin-off from Ghent University and Imec, raised USD 10.7 million to develop a photonic-based therapeutic drug monitoring platform. The technology aims to accurately and efficiently measure drug concentrations in blood, initially focusing on beta-lactam antibiotics for intensive care patients
- In February 2023, Sentinel Diagnostics acquired Eureka S.r.l., enhancing its capabilities in in vitro diagnostic testing. This acquisition allows Sentinel to offer a broader range of assays, including those for therapeutic drug monitoring, by incorporating Eureka's expertise in chromatographic applications
- In May 2022, THERADIAG introduced ez-Track1, a Point-of-Care Testing (POCT) solution designed for rapid therapeutic drug monitoring. The CE-marked system delivers results within 10 minutes using whole blood samples, facilitating swift decision-making in implementing biotherapies
